Arrowhead’s small interfering RNA therapy reduced triglycerides and lowered pancreatitis risk in the phase 3 PALISADE trial, providing a quarterly self-administered option for patients with familial chylomicronemia syndrome.
Proposed cuts to the Hospital Preparedness Program may limit hospitals’ capacity to manage pandemics, natural disasters, and mass-casualty events affecting U.S. health systems.
Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
“These findings indicate that standardized efficacy, safety, and risk assessment reporting remains inadequate for FDA-cleared AI/ML devices, underscoring the need for dedicated regulatory pathways and robust postmarket surveillance to ensure patient safety."
HHS Secretary Robert F. Kennedy Jr.’s changes at the CDC are prompting states and medical societies to issue independent vaccine recommendations, challenging long-standing national immunization policy.
Testimony from former CDC leadership highlighted differences with federal health officials on the process for reviewing and implementing vaccine policies.